Back to Archived News
ImmunoCellular Therapeutics Names Interim President, Files Key Patent Applications
Wednesday, November 14, 2007
Los Angeles, CA -- ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC) ("IMUC") announced today that it has named C. Kirk Peacock to serve as its Interim President. Mr. Peacock, who has served on a part-time basis as IMUC’s Chief Financial Officer since January 2006, will also now serve as IMUC’s Interim President on a part-time basis.
"We are pleased that Kirk Peacock has agreed to serve on an interim basis as our President," said Dr. John Yu, IMUC’s Chairman of the Board. "We have launched an aggressive search to hire a full-time Chief Executive Officer with expertise and a proven track record of success in managing an early stage biopharmaceutical company like ours."
IMUC also announced today that it has filed with the U.S. patent office the two principal applications covering its multiple antigen dendritic cell cancer vaccine and cancer stem cell vaccine technologies that were the subject of provisional patent applications previously filed with the U.S. patent office. IMUC currently is funding a Phase I trial of the first technology and is evaluating certain pre-clinical data for its cancer stem cell vaccine technology to assess the feasibility of initiating a clinical development program for this technology in the treatment of brain tumors.
About ImmunoCellular Therapeutics
IMUC is a Los Angeles, California based development stage company that will seek to develop cellular therapies for the treatment of brain and other cancers as well as neurodegenerative disorders. IMUC’s initial focus will be on a dendritic cell-based vaccine for treating brain tumors, with a Phase I trial for its lead vaccine product candidate having commenced in May 2007.
This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including without limitation a potential delay in hiring a Chief Executive Officer or inability to hire a Chief Executive Officer with the appropriate qualifications, an early termination by Kirk Peacock of his employment as Interim President and Chief Financial Officer under the terms of his agreement with IMUC, IMUC’s failure to obtain patent coverage or only very narrow patent coverage for its technologies, the potential ability of third parties to successfully challenge any patents issued to IMUC or to commercialize similar technologies that do not infringe any patents issued to IMUC, the risk associated with clinical development of IMUC’s multiple antigen dendritic cell vaccine, including without limitation potential delays in patient enrollment, adverse safety results or inadequate efficacy, and the risks associated with development of IMUC’s cancer stem cell vaccine, including potentially insufficient data to support clinical data or delays in obtaining or inability to obtain FDA approval to commence any clinical trials. Additional risks and uncertainties are described in IMUC’s most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-QSB and any current reports on Form 8-K. IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Back to Archived News